AI Brings Hope for Patients with Lyosomal Storage Disease

The role of artificial intelligence (AI) in drug discovery is expanding. Researchers at the University of Zurich (UZH) have now been able to better understand a significant metabolic disorder because to advancements in the use of Big Data, learning algorithms, and powerful computers.

The worldwide prevalence of cystinosis, a rare lyosomal storage condition, ranges from 1 in 100,000 to 200,000 infants. The most prevalent and serious type of cystinosis, nephropathic (non-inflammatory), begins to show signs of kidney disease in the first few months of infancy and frequently results in renal failure by the age of ten. According to Olivier Devuyst, co-director of the ITINERARE University Research Centre and leader of the Mechanisms of Inherited Kidney Disorders (MIKADO) group, "Children with cystinosis suffer from a devastating, multisystemic disease, and there are currently no available curative treatments."